LEXINGTON, Mass., Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology companydevoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will hold a conference call on Thursday, August 9, 2018, at 8:00 a.m. EDT
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.
About Aldeyra TherapeuticsAldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune and metabolic diseases. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Corporate Contact:David McMullinAldeyra Therapeutics, Inc.Tel: 781-761-4904 ext. 218 email@example.com
Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843Chris.firstname.lastname@example.org
Media Contact:Cammy Duong MacDougall Biomedical Communications email@example.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-second-quarter-2018-financial-results-and-corporate-update-300690941.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All